The MADIT II and Companion studies: Will they affect uptake of device treatment?

Heart

Volumn 90, Issue 3, 2004, Pages 243-245

  Morgan, J M ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOMYOPATHY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; DEFIBRILLATOR; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE ARRHYTHMIA; HIGH RISK POPULATION; HUMAN; IMPLANTATION; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; RISK ASSESSMENT; SUDDEN DEATH; UTILIZATION REVIEW;

EID: 1342280428     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2002.007807     Document Type: Review

References (26)

1. Jimenez RA, Myerburg RJ. Sudden cardiac death. Magnitude of the problem, substrate/trigger interaction, and populations at high risk. Cardiol Clin 1993;11:1-9.
2. Priori SG, Borggrefe M, Camm AJ, et al. Unexplained cardiac arrest. The need for a prospective registry. Eur Heart J 1992;13:1445-6.
3. Alexander S. Conversion of cardiac arrhythmias by electrical countershock: method, results and indications. Lahey Clin Found Bull 1965;14:49-57.
4. Friedberg CK, Lyon LJ, Donoso E. Suppression of refractory recurrent ventricular tachycardia by transvenous rapid cardiac pacing and antiarrhythmic drugs. Report of seven cases. Am Heart J 1970;79:44-50.
5. Wietholt D, Block M, Isbruch F, et al. Clinical experience with antitachycardia pacing and improved detection algorithms in a new implantable cardioverter-defibrillator. J Am Coll Cardiol 1993;21:885-94.
6. Bonnet CA, Fogoros RN, Elson JJ, et al. Long-term efficacy of an antitachycardia pacemaker and implantable defibrillator combination. Pacing Clin Electrophysiol 1991;14(5 Pt 1):814-22.
7. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933-40.
8. The Antiarrhythmics versus Implantable Defibrilators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-84.
9. Mirowski M, Reid PR, Mower MM, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 1980;303:322-4.
10. Bardy GH, Hofer B, Johnson G, et al. Implantable transvenous cardioverter-defibrillators. Circulation 1993;87:1152-68.
11. Yee R, Klein GJ, Leitch JW, et al. A permanent transvenous lead system for an implantable pacemaker cardioverter-defibrillator. Nonthoracotomy approach to implantation. Circulation 1992;85:196-204.
12. American Colege of Cardiology/American Heart Association Task Force on Practice Guidelines. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices, 2002.
13. National Institute for Clinical Excellence. Guidance on the use of implantable cardioverter defibrilllator for arrhythmias. www.nice.org Technology appraisal guidance number 11, 2000.
14. Cleland JG, Chattopadhyay S, Khand A, et al. Prevalence and incidence of arrhythmias and sudden death in heart failure. Heart Fail Rev 2002;7:229-42.
15. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter unsustained tachycardia trial investigators. N Engl J Med 1999;341:1882-90.
16. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
17. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845-53.
18. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001;344:873-80.
19. Coats AJ. MADIT II, the multi-center autonomic defibrillator implantation trial II stopped early for mortality reduction: has ICD therapy earned its evidence-based credentials? Int J Cardiol 2002;82:1-5.
20. Plummer CJ, Irving RJ, McComb JM. Implications of national guidance for implantable cardioverter defibrillation implantation in the United Kingdom. Pacing Clin Electrophysiol 2003;26(1 Pt 2):479-82.
21. Moss AJ. MADIT-II and its implications. Eur Heart J 2003;24:16-18.
22. Iuliano S, Fisher SG, Karasik PE, et al. QRS duration and mortality in patients with congestive heart failure. Am Heart J 2002;143:1085-91.
23. Auricchio A, Stellbrink C, Block M, et al. Effect of patients with congestive heart failure. The pacing therapies for congestive heart failure study group. The Guidant congestive heart failure research group. Circulation 1999;99:2993-3001.
24. Salukhe TV, Francis DP, Sutton R. Comparison of medical therapy, pacing and defibrillation in heart failure (COMPANION) trial terminated early; combined biventricular pacemaker-defibrillators reduce all-cause mortality and hospitalization. Int J Cardiol 2003;87:119-20.
25. Cleland JG, Daubert JC, Erdmann E, et al. The CARE-HF study (cardiac resynchronisation in heart failure study): rationale, design and end-points. Eur J Heart Fail 2001;3:481-9.
26. Klein H, Aurrichio A, Reek S, et al. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. Am J Cardiol 1999;83(suppl D):91D-7D.